Sumgen is an innovative biopharmaceutical company dedicated to the creation and commercialization of antibody therapeutics for cancer and other serious diseases.
We are led by a professional team and consultative committee made up of members of Chinese Academy of Science and Engineering and other experts highly experienced in the development of antibody drugs and their industrialization. Three world-leading R&D centers have been built, with headquarters in Hangzhou and two other centers in Beijing and Shanghai. We successfully developed an integrated process covering drug discovery, manufacturing and clinical development. Our proprietary product pipeline currently is focused on broad immuno-oncology targets, with SG001, SG301, SG404 and SG12473 projects in the clinical study stage.
We have been awarded such honors as “Hangzhou Binjiang 5050 Plan (Class B)”, a “National High-tech Enterprise” and a “Zhejiang Technology R&D Center”. We secured capital from Hankang Capital, National Vaccine & Serum Institute, Addor Capital, Sinowisdom and Cowin Capital, and we partnered with many representative enterprises, including CSPC and National Vaccine & Serum Institute.At present, we have started the construction of a state-of-the-art manufacturing site, with the aim of building a "complete industrial chain" (Innovative R&D - Clinical Transformation - Industrialization). We strive to become a world leading biopharmaceutical enterprise with the capability of sustaining innovation.
Inspired by the spirit of "Better Innovation, Better Lives", we have a mission to deliver high-quality biopharmaceutical products to patients throughout the world.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044